SG11201903803UA - Aldosterone synthase inhibitor - Google Patents
Aldosterone synthase inhibitorInfo
- Publication number
- SG11201903803UA SG11201903803UA SG11201903803UA SG11201903803UA SG11201903803UA SG 11201903803U A SG11201903803U A SG 11201903803UA SG 11201903803U A SG11201903803U A SG 11201903803UA SG 11201903803U A SG11201903803U A SG 11201903803UA SG 11201903803U A SG11201903803U A SG 11201903803UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- walchwil
- haltli
- english
- Prior art date
Links
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002478 aldosterone Drugs 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004817 gas chromatography Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- LENLQGBLVGGAMF-UHFFFAOYSA-N tributyl([1,2,4]triazolo[1,5-a]pyridin-6-yl)stannane Chemical compound C1=C([Sn](CCCC)(CCCC)CCCC)C=CC2=NC=NN21 LENLQGBLVGGAMF-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662413635P | 2016-10-27 | 2016-10-27 | |
EP16205019 | 2016-12-19 | ||
PCT/EP2017/077511 WO2018078049A1 (en) | 2016-10-27 | 2017-10-26 | Aldosterone synthase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903803UA true SG11201903803UA (en) | 2019-05-30 |
Family
ID=60162205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903803UA SG11201903803UA (en) | 2016-10-27 | 2017-10-26 | Aldosterone synthase inhibitor |
Country Status (13)
Country | Link |
---|---|
US (3) | US10822332B2 (es) |
EP (1) | EP3532056A1 (es) |
JP (2) | JP7130636B2 (es) |
KR (2) | KR102506380B1 (es) |
CN (2) | CN109890389B (es) |
AU (2) | AU2017350484B2 (es) |
BR (1) | BR112019007954A2 (es) |
CA (1) | CA3040803A1 (es) |
CL (1) | CL2019001131A1 (es) |
IL (2) | IL301471A (es) |
MX (2) | MX2019004937A (es) |
SG (1) | SG11201903803UA (es) |
ZA (1) | ZA201903149B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102506380B1 (ko) * | 2016-10-27 | 2023-03-03 | 다미안 파르마 에이쥐 | 알도스테론 합성효소 저해제 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428160A (en) * | 1982-12-21 | 1995-06-27 | Ciba-Geigy Corporation | Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives |
MTP1076B (en) | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
NZ521855A (en) | 2000-04-12 | 2004-10-29 | Novartis Ag | Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a dirruretic to treat various conditions |
WO2005099695A1 (en) * | 2004-04-19 | 2005-10-27 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
EP1842543A1 (en) * | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
EP1886695A1 (en) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
IN2014DN06781A (es) * | 2012-01-17 | 2015-05-22 | Novartis Ag | |
KR102506380B1 (ko) * | 2016-10-27 | 2023-03-03 | 다미안 파르마 에이쥐 | 알도스테론 합성효소 저해제 |
-
2017
- 2017-10-26 KR KR1020197011358A patent/KR102506380B1/ko active IP Right Grant
- 2017-10-26 AU AU2017350484A patent/AU2017350484B2/en active Active
- 2017-10-26 SG SG11201903803UA patent/SG11201903803UA/en unknown
- 2017-10-26 JP JP2019522665A patent/JP7130636B2/ja active Active
- 2017-10-26 CN CN201780065333.4A patent/CN109890389B/zh active Active
- 2017-10-26 BR BR112019007954A patent/BR112019007954A2/pt unknown
- 2017-10-26 KR KR1020237007198A patent/KR20230037680A/ko not_active Application Discontinuation
- 2017-10-26 CA CA3040803A patent/CA3040803A1/en active Pending
- 2017-10-26 US US16/345,209 patent/US10822332B2/en active Active
- 2017-10-26 IL IL301471A patent/IL301471A/en unknown
- 2017-10-26 EP EP17787936.8A patent/EP3532056A1/en active Pending
- 2017-10-26 CN CN202210638632.5A patent/CN114853755A/zh active Pending
- 2017-10-26 MX MX2019004937A patent/MX2019004937A/es unknown
-
2019
- 2019-04-16 IL IL266056A patent/IL266056B2/en unknown
- 2019-04-25 CL CL2019001131A patent/CL2019001131A1/es unknown
- 2019-04-26 MX MX2022006934A patent/MX2022006934A/es unknown
- 2019-05-20 ZA ZA2019/03149A patent/ZA201903149B/en unknown
-
2020
- 2020-08-12 US US16/991,856 patent/US11447491B2/en active Active
-
2022
- 2022-03-01 AU AU2022201401A patent/AU2022201401B2/en active Active
- 2022-08-09 US US17/883,732 patent/US20230047158A1/en active Pending
- 2022-08-24 JP JP2022133021A patent/JP2022176994A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3040803A1 (en) | 2018-05-03 |
AU2022201401A1 (en) | 2022-03-24 |
CN109890389A (zh) | 2019-06-14 |
JP2019532975A (ja) | 2019-11-14 |
BR112019007954A2 (pt) | 2019-07-02 |
KR20190071715A (ko) | 2019-06-24 |
CL2019001131A1 (es) | 2019-09-06 |
US10822332B2 (en) | 2020-11-03 |
US20210024519A1 (en) | 2021-01-28 |
IL266056B2 (en) | 2023-08-01 |
CN114853755A (zh) | 2022-08-05 |
MX2022006934A (es) | 2022-07-11 |
CN109890389B (zh) | 2022-07-01 |
JP7130636B2 (ja) | 2022-09-05 |
MX2019004937A (es) | 2019-06-24 |
ZA201903149B (en) | 2020-02-26 |
AU2022201401B2 (en) | 2024-02-15 |
KR20230037680A (ko) | 2023-03-16 |
AU2017350484B2 (en) | 2021-12-02 |
KR102506380B1 (ko) | 2023-03-03 |
JP2022176994A (ja) | 2022-11-30 |
US11447491B2 (en) | 2022-09-20 |
US20190292180A1 (en) | 2019-09-26 |
US20230047158A1 (en) | 2023-02-16 |
IL266056B1 (en) | 2023-04-01 |
AU2017350484A1 (en) | 2019-05-23 |
IL301471A (en) | 2023-05-01 |
EP3532056A1 (en) | 2019-09-04 |
IL266056A (en) | 2019-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201908977SA (en) | Niraparib formulations | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201903892UA (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
SG11201808676RA (en) | Methods of treating pediatric cancers | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201806424TA (en) | Therapeutic compounds | |
SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
SG11201807979SA (en) | Palatable compositions including sodium phenylbutyrate and uses thereof |